Certain DNA mutations in bone cells that support blood development can drive leukaemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children's Healthcare of Atlanta have found.

Many cancer-driving mutations are "cell-autonomous," meaning that the change in a cell's DNA makes that same cell grow more rapidly.

In contrast, an indirect Noonan syndrome, an inherited disorder that increases the risk of developing leukaemia.

The findings are scheduled for publication in Nature.

The leukaemias in Noonan syndrome patients.

That's because bone marrow transplant may remove the cancerous cells, but not the cause of the problem, leading to disease recurrence.

However, the researchers show that a class of drugs can dampen the cancer-driving neighbour effect in mice.

One of the drugs, maraviroc, is already FDA-approved against HIV infection.

Noonan syndrome often involves short stature, distinctive facial features, congenital heart defects and bleeding problems.

It occurs in between one in 1000 to one in 2500 people, and can be caused by mutations in several genes.

The most common cause is mutations in the gene PTPN11. Children with Noonan syndrome are estimated to have a risk of developing leukaemia or other cancers that is eight times higher than their peers.

"Our research highlights the importance of the bone marrow microenvironment," says Cheng-Kui Qu, MD, PhD, professor of paediatrics at Emory University School of Medicine, Winship Cancer Institute and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta. "We found that a disease-associated mutation, which disturbs the niches where blood stem cell development occurs, can lead to leukaemia formation."

Previous research had established that mutations in PTPN11 have a conventional cell-autonomous effect on blood stem cells' growth.

In the current paper, researchers led by Qu show that PTPN11 mutations also affect mesenchymal stem cells, which normally nurture blood stem cells within specific niches in the bone marrow.

Mesenchymal stem cells cannot become blood cells themselves.

The mutations cause the mesenchymal stem cells to over-produce a signal called CCL3, which attracts immune cells called monocytes into the blood stem cells' niches.

As a result, the monocytes make inflammatory molecules that stimulate the blood stem cells to differentiate and proliferate, leading to leukaemias.

"We have identified CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonan syndrome-associated leukaemias," Qu says.

Qu's team had started out intending to investigate the effects of PTPN11 mutations in the nervous system.

The team developed genetically engineered mice that altered PTPN11 in neural cells, and saw that the mice all developed an enlarged spleen and a condition resembling myeloproliferative disorder (too many monocytes) at an early age.

It turned out that their mice had also changed the PTPN11 gene in mesenchymal stem cells, but not blood stem cells.

The myeloproliferative disorder in the PTPN11-mutant mice can be treated in the short term by bone marrow transplant, but it comes back within months.

The research team showed that drugs that counteract CCL3 dampen the myeloproliferative disorder in the mutant mice.

One of them is maraviroc, which has been FDA-approved to combat HIV infection, and another is BX471, which was under development for multiple sclerosis.

The authors caution that other Noonan syndrome mutations, in genes besides PTPN11, need to be assessed for their effects on leukaemia formation.

Source: Nature